Here, we confirm these observations and additionally, our study highlights the efficacy of this combination especially on melanoma cells rather than healthy surrounding cells, and also importantly in the context of acquired and intrinsic BRAF inhibitor resistance. The gene discussed is BRAF; the disease is melanoma.